Wire · operational-macro
FDA Accepts BLA For Formycon And Zydus' Keytruda Biosimilar FYB206 ;Shares Rise
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 13 October 2026 · Fusion42 review
The FDA has accepted the Biologics License Application (BLA) for FYB206, a biosimilar to Keytruda developed by Formycon and Zydus, potentially paving the way for a new competitor in the immuno-oncology market.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
FDA acceptance of a Keytruda biosimilar opens up the US immuno-oncology market to new competition. You need to assess how this affects your market entry or partnership timing to capitalise on emerging biosimilar demand.
◆ Coverage
1 source · 13 Oct 2026
◆ Related on Wire
◆ Topics
Biotechfda-approvalbiosimilarkeytrudaimmuno-oncology